Table 1. Baseline characteristics of the patients.
| Characteristic | Group A (n=74) | Group B (n=74) | P value |
|---|---|---|---|
| Age (year) | 62.35±7.37 | 63.08±7.29 | 0.5456 |
| Male sex, n (%) | 42(56.75) | 45(60.81) | 0.616 |
| BMI(kg/m2) | 23.6±2.5 | 24.2±3.5 | 0.2321 |
| Hypertension, n (%) | 26(35.13) | 32(43.24) | 0.312 |
| Diabetes mellitus, n (%) | 15(20.27) | 25(33.78) | 0.064 |
| Smoking, n (%) | 37(50.00) | 49(58.33) | 0.046 |
| Hyperlipidaemia, n (%) | 32(43.24) | 21(28.37) | 0.059 |
| Previous CABG, n (%) | 3(4.05) | 8(10.81) | 0.117 |
| Previous MI, n (%) | 17(22.97) | 6(8.10) | 0.013 |
| LVEF, n(%) | 55.39±8.04 | 54.46±7.89 | 0.4787 |
| Albumin (g/L) | 34.23±6.39 | 37.36±7.03 | 0.0052 |
| TC (mg/dL) | 172.03±14.28 | 173.29±12.98 | 0.5752 |
| HDL-C (mg/dL) | 34.55±5.32 | 36.47±6.35 | 0.0480 |
| LDL-C (mg/dL) | 106.46±12.39 | 109.77±14.34 | 0.1351 |
| Scr before treatment (umol/L) | 98.23±12.73 | 96.79±13.47 | 0.5050 |
| cystatin C before treatment (mg/L) | 1.06±0.25 | 1.01±0.22 | 0.1985 |
| eGFR before treatment (ml/min) | 82.25±8.16 | 84.92±8.79 | 0.0574 |
| Renal insufficiency, n (%) | 0(0) | 0(0) | NS |
| Iodixanol dosage (ml) | 125.32±10.28 | 129.47±11.34 | 0.0210 |
| Treatment received | |||
| Aspirin, n (%) | 74(100) | 74(100) | NS |
| Clopidogrel sulfate, n (%) | 74(100) | 74(100) | NS |
| ACEIs/ARBs, n (%) | 62(83.78) | 51(68.91) | 0.033 |
| Beta-blockers, n (%) | 67(90.54) | 54(72.97) | 0.006 |
| Calcium antagonists, n (%) | 31(41.89) | 26(35.13) | 0.398 |
| Nitrates, n (%) | 39(52.70) | 31(41.89) | 0.188 |
| GPIIb/IIIa inhibitors, n (%) | 26(35.13) | 9(12.16) | 0.001 |
Data are presented as number (percent) or mean±SD.
BMI=Body mass index; CABG=coronary artery bypass grafting, MI=myocardial infarction, LVEF=Left ventricular ejection fraction; TC=Total cholesterol; HDL-C=High density lipoprotein; LDL-C=Low density lipoprotein; Scr=serum creatinine; eGFR=glomerular filtration rate; ACEIs=Angiotensin-converting enzyme inhibitors; ARBs=Angiotensin-receptor blockers; GPIIb/IIIa inhibitors=Glycoprotein IIb/IIIa inhibitors; NS=Not significant.